Alkermes plc (ALKS)
NASDAQ: ALKS · Real-Time Price · USD
27.15
+0.04 (0.15%)
Apr 23, 2025, 4:00 PM EDT - Market closed
Alkermes Revenue
In the year 2024, Alkermes had annual revenue of $1.56B, down -6.36%. Alkermes had revenue of $429.99M in the quarter ending December 31, 2024, with 13.91% growth.
Revenue (ttm)
$1.56B
Revenue Growth
-6.36%
P/S Ratio
2.88
Revenue / Employee
$865,351
Employees
1,800
Market Cap
4.48B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.56B | -105.77M | -6.36% |
Dec 31, 2023 | 1.66B | 551.61M | 49.61% |
Dec 31, 2022 | 1.11B | -61.96M | -5.28% |
Dec 31, 2021 | 1.17B | 135.00M | 13.00% |
Dec 31, 2020 | 1.04B | -132.19M | -11.29% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
ALKS News
- 6 days ago - Alkermes to Report First Quarter Financial Results on May 1, 2025 - PRNewsWire
- 21 days ago - Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference - PRNewsWire
- 22 days ago - Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia - PRNewsWire
- 27 days ago - New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder - PRNewsWire
- 2 months ago - Alkermes to Participate in Upcoming Investor Conferences - PRNewsWire
- 2 months ago - Alkermes' Neuroscience Pivot: ALKS 2680 Set To Revolutionize Narcolepsy Treatment - Seeking Alpha
- 2 months ago - Alkermes plc (ALKS) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025 - PRNewsWire